Im Fokus Onkologie最新文献

筛选
英文 中文
Diente Krebs als „Alibi“ für einen Mord? 癌症是谋杀的 "不在场证明 "吗?
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3755-z
Lamia Özgör
{"title":"Diente Krebs als „Alibi“ für einen Mord?","authors":"Lamia Özgör","doi":"10.1007/s15015-024-3755-z","DOIUrl":"https://doi.org/10.1007/s15015-024-3755-z","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immuntherapie: Keine Angst vor den Nebenwirkungen 免疫疗法:不要害怕副作用
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3805-6
Mascha Pömmerl
{"title":"Immuntherapie: Keine Angst vor den Nebenwirkungen","authors":"Mascha Pömmerl","doi":"10.1007/s15015-024-3805-6","DOIUrl":"https://doi.org/10.1007/s15015-024-3805-6","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wie sieht die Onkologie in der Zukunft aus? 未来的肿瘤学会是什么样子?
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3809-2
Redaktion Facharztmagazine
{"title":"Wie sieht die Onkologie in der Zukunft aus?","authors":"Redaktion Facharztmagazine","doi":"10.1007/s15015-024-3809-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3809-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TNBC: Toripalimab plus nab-Paclitaxel verzögert die Progression TNBC:托利帕单抗联合纳布-紫杉醇抑制病情恶化
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3790-9
Robert Bublak
{"title":"TNBC: Toripalimab plus nab-Paclitaxel verzögert die Progression","authors":"Robert Bublak","doi":"10.1007/s15015-024-3790-9","DOIUrl":"https://doi.org/10.1007/s15015-024-3790-9","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Das ist neu in der Leitlinie Ösophaguskarzinom 食道癌指南的新内容
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3761-1
E. Oberhofer
{"title":"Das ist neu in der Leitlinie Ösophaguskarzinom","authors":"E. Oberhofer","doi":"10.1007/s15015-024-3761-1","DOIUrl":"https://doi.org/10.1007/s15015-024-3761-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140792336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RCC: Länger progressionsfrei mit Cabozantinib RCC:使用卡博替尼可获得更长的无进展时间
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3807-4
Redaktion Facharztmagazine
{"title":"RCC: Länger progressionsfrei mit Cabozantinib","authors":"Redaktion Facharztmagazine","doi":"10.1007/s15015-024-3807-4","DOIUrl":"https://doi.org/10.1007/s15015-024-3807-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weniger Dysphagie dank optimierter Strahlentherapie 优化放射治疗,减少吞咽困难
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3779-4
Marie-Thérèse Weitzl
{"title":"Weniger Dysphagie dank optimierter Strahlentherapie","authors":"Marie-Thérèse Weitzl","doi":"10.1007/s15015-024-3779-4","DOIUrl":"https://doi.org/10.1007/s15015-024-3779-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumortherapiefelder verlängern Überlebenszeit bei NSCLC 肿瘤治疗场可延长非小细胞肺癌患者的生存时间
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3777-6
T. Müller
{"title":"Tumortherapiefelder verlängern Überlebenszeit bei NSCLC","authors":"T. Müller","doi":"10.1007/s15015-024-3777-6","DOIUrl":"https://doi.org/10.1007/s15015-024-3777-6","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HR-positiver BC: Adjuvant therapieren gemäß dem individuellen Risiko HR 阳性 BC:根据个体风险进行辅助治疗
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3804-7
Mascha Pömmerl
{"title":"HR-positiver BC: Adjuvant therapieren gemäß dem individuellen Risiko","authors":"Mascha Pömmerl","doi":"10.1007/s15015-024-3804-7","DOIUrl":"https://doi.org/10.1007/s15015-024-3804-7","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140795551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eltrombopag bei Niedrig-Risiko-MDS mit Thrombozytopenie wirksam 艾曲波帕对伴有血小板减少的低风险 MDS 有效
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3769-6
F. Klein
{"title":"Eltrombopag bei Niedrig-Risiko-MDS mit Thrombozytopenie wirksam","authors":"F. Klein","doi":"10.1007/s15015-024-3769-6","DOIUrl":"https://doi.org/10.1007/s15015-024-3769-6","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140795422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信